TROY THIELEN: Open Payments
NPI 1720445810 · OKEMOS, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,856 in 104 payments from 19 companies in 2025. Trend: 2023 $1,341 · 2024 $2,042 · 2025 $1,856
Food & beverage: $1,856
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 20 | $352 |
| ABBVIE INC. | 16 | $219 |
| Vanda Pharmaceuticals Inc. | 9 | $196 |
| AstraZeneca Pharmaceuticals LP | 6 | $173 |
| Otsuka America Pharmaceutical, Inc. | 7 | $167 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 15 | $138 |
| Axsome Therapeutics, Inc. | 6 | $134 |
| Amgen Inc. | 6 | $99 |
| GlaxoSmithKline, LLC. | 5 | $92 |
| Lundbeck LLC | 3 | $58 |
Products named: REXULTI, FANAPT, AIRSUPRA, CAPLYTA, Auvelity, Ozempic, VRAYLAR, Wegovy.
Industry payments across MI — which companies pay providers there.
